National Jewish Health

Milene Saavedra

Jerry A Nick

Vijaya Knight

The present invention is related to novel methods for categorizing and treating a population of subjects having cystic fibrosis (CF) and who are at risk of severe pulmonary exacerbation comprising detecting the expression levels of genes in a gene panel consisting of TLR2, ADAM9, PLXND1, CD163, CD36, CD64, CSPG2, IL32, HPSE, and HCA112 and aggressively treating the subject when the expression levels of the genes from the gene panel predicts the subject is at risk for severe pulmonary exacerbation.

Methods for categorizing and treating subjects having cystic fibrosis (CF) and at risk for severe pulmonary exacerbation

The present invention is related to novel methods for for determining pulmonary disease progression severity in a subject having cystic fibrosis by detecting mRNA expression levels of CD64 in a whole blood sample for the subject and calculating a disease risk score, wherein the disease risk score correlates to the risk score for mild, moderate or severe pulmonary disease progression at exacerbation and treating the subject accordingly.

Methods for categorizing and treating subjects at risk for pulmonary exacerbation and disease progression

The present invention is related to novel methods for diagnosing and treating acute pulmonary exacerbation in subjects in need thereof.

Methods for diagnosing and treating subjects for pulmonary exacerbation

The present invention is related to a method for determining pulmonary disease progression severity in a subject having cystic fibrosis and treating the subject according to the severity. The method comprises obtaining a whole blood sample from the subject; detecting the mRNA expression level of each of the following genes: TLR2, ADAM9, PLXND1, CD163, CD36, CD64, CSPG2, IL32, HPSE, HCA112; determining the severity of the pulmonary disease progression based on the subject's combined mRNA expression level of the genes; and treating the subject.

Method for treating pulmonary exacerbation and disease progression in subjects having cystic fibrosis

The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.

Markers for diagnosis of pulmonary inflammation and methods related thereto

The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA 112, CSPG2, TLR2, and CD163.

Growing community of inventors

Denver, CO, United States of America

Milene Saavedra